Across TCGA pan-cancer cohorts, RBM20 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RBM20 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RBM20 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM20 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

ACC, COAD, and UCEC are the cancer types where RBM20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.053	0.675	<.001	18	view →
COAD	DFS	Median	All	1.000	0.441	.012	11	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RBM20 tumor-vs-normal RNA expression · all RBM20 data types